Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) ca...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rumi, Elisa, Pietra, Daniela, Pascutto, Cristiana, Guglielmelli, Paola, Martínez-Trillos, Alejandra, Casetti, Ilaria, Colomer, Dolors, Pieri, Lisa, Pratcorona, Marta, Rotunno, Giada, Sant’Antonio, Emanuela, Bellini, Marta, Cavalloni, Chiara, Mannarelli, Carmela, Milanesi, Chiara, Boveri, Emanuela, Ferretti, Virginia, Astori, Cesare, Rosti, Vittorio, Cervantes, Francisco, Barosi, Giovanni, Vannucchi, Alessandro M., Cazzola, Mario
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2014
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133481/
https://ncbi.nlm.nih.gov/pubmed/24986690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-578435
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller